Eligard (leuprorelin acetate) | For UK Healthcare Professionals
As few as two injections per year (with 6‑monthly dosing option).1
Sustained testosterone suppression.1
Over 20 years of experience.*2
ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1
and efficacy and safety data from over 17 published clinical trials, you can be assured that ELIGARDâ„¢ will reliably suppress testosterone for as long as your patients need1-7
References
Information on the processing of personal data for Medical Information,Â
Safety Reporting and Product Quality Complaint – click here
UK-ELIGA-0050 | September 2026 © 2026 Recordati
This promotional website from Recordati is intended for UK healthcare professionals. Please confirm that you are a healthcare professional based in the UK by clicking below:
UK-ELIGA-0072 August 2026